期刊文献+

鼻咽癌放射治疗IMRT与Arc调强计划的剂量学比较 被引量:4

A dosimetric comparison between IMRT and Arc treatment plan for nasopharyngeal carcinoma
在线阅读 下载PDF
导出
摘要 目的分析鼻咽癌放射治疗IMRT与Rapid Arc调强放疗计划方案,为临床提供参考。方法 10例鼻咽癌CT增强扫描模拟定位后勾画CTV,按统一标准外扩PTV;实施均分9野IMRT计划和单弧、双弧、3弧Arc调强计划;以PTV处方剂量70Gy,分析各治疗计划靶区剂量分布和危及器官受限剂量,进行剂量学对比研究并比较治疗时间的长短。结果 IMRT调强计划适形指数及不均匀指数明显优于单弧,与双弧和3弧没有明显区别;各计划之间危及器官受量均低于参考受限剂量;照射体积(irradiation volume,IV)未见明显区别;机器跳数(monitor unit,MU),Arc调强计划明显低于IMRT调强计划;治疗时间上Arc调强计划更短。结论目前虽IMRT计划更符合鼻咽癌的治疗剂量要求,但Arc计划在缩短治疗时间、降低治疗时的机器跳数上有明显优势。 Objective To examine intensity modulated radiation therapy (IMRT) and Rapid Arc treatment plan for nasopharyngeal carcinoma,and to provide a reference fl^r clinical selection of radiotherapy plans. Methods Ten patients with nasophalTngeal carci- noma(NPC ) were enrolled and underwent CT simulation.The clinical target volume(CTV) was contoured on the CT image,and the planning target volume(PTV ) was defined according to the same criteria.Nine-field IMRT(IMRT9), single arc(Arcl ),double arc (Arc2) and triple arc (Arc 3) Rapid Arc plans were generated for each patient.All plans were prescribed 70 Gy.The dosimetric pa- rameters of target volume and organ at risk (OAR),the monitor units (MU) and treatment time were compared between IMRT and arc treatment plan. Results The conformity index (CI) and HI of PTV for IMRT were superior to those for Arcl ,and were similar to those for Arc2 and Arc3,and all the OAR for various plans were lower than the reference limited dose.MU of Arc was significantly lower than that of IMRT plan,and treatment time of Arc was shorter than that of IMRT. Conclusions Although the IMRT plan is recom- mended for dosimetry, the Arc plan shows a distinct advantage for its short treatment time and small MU number.
出处 《中国癌症防治杂志》 CAS 2012年第3期225-228,共4页 CHINESE JOURNAL OF ONCOLOGY PREVENTION AND TREATMENT
基金 国家自然科学基金资助项目(11105236)
关键词 鼻咽肿瘤 放射治疗 IMRT/Arc调强计划 Nasopharyngeal neoplasms Radiotherapy Intensity modulated/Rapid Arc
  • 相关文献

参考文献8

  • 1Mundt AJ,Roeske JC.Can intensity-modulated radiation therapy re- place brachytherapy in the management of cervical cancer counter- point[J].Brachytherapy, 2002, 1(4):192-194.
  • 2Marcus R.Intensity-modulated radiation therapy for gynecologic can- cers:pitfalls,hazards and cautions to he considered-J ].Radiation On- cology, 2006,16(3):138-143.
  • 3谷铣之,殷蔚伯,余子豪,等.肿瘤放射治疗学[M].北京:中国协和医科大学出版社,2008:573.
  • 4Van't Riet A,Mak AC,Moerland MA,ct al.A conformation number to quantify the degree of conformality in brachytherapy and external beam irradiation application to the prostatc[J ].lnt J Rad Oncol Biol Phys, 1997, 37( 3 ): 731-736.
  • 5Bragg GM,Conway J, Robinson MH. The role of intensity-modulated radiotherapy in the treatment of parotid tumors[J-.Int J Rad Oncol Biol Phys, 2002, 52(3 ):729-738.
  • 6[美]K.S.Clifford著.冯平柏译.实用肿瘤训强放疗治疗学[M].见CliffordKS著.南京:江苏科学技术出版社,2006:29-31.
  • 7Kry SF,Salehpour M,Followill DS,et al.The calculated risk of falal secondary malignancies from intensity-modulated radiation therapy [J].Int J Radial Oncol Biol Phys,2005,62(4):1195-1203.
  • 8Hall E,Se D.MRT protons and the risk of second cancer[J].lnt J Rad Oncol Biol Phys, 2006,65: 1-7.

共引文献78

同被引文献42

  • 1吴德华,耿炜,陈永清,陈龙华.颈段胸上段食管癌三维适形放射治疗疗效观察[J].中华放射肿瘤学杂志,2004,13(4):270-272. 被引量:48
  • 2Tong DK, Law S,Wong KH, et al. Current management of eervi-cal esophageal cancer[J].World J Surg,2011,35(3):600 607.
  • 3Chou SH, Huang MF, Lee KW, et al. Radical resection or chemo- radiotherapy for cervical esophageal cancer? [J]. Word J Surg, 2010,34(8) :1832-1839.
  • 4Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group(RTOG) and the European Organization for Re- search and Treatment of Cancer(EORTC)[J]. Int J Radiat Oncol Biol Phys,1995,31(5) :1341 1346.
  • 5Takeuchi H, Saikawa Y, Kitagawa Y, et al. Factors influencing the long-term survival in patients with esophageal cancer who underwent esophageetomy after chemoradiotherapy[J]. World J Surg,2010,34(2) 277-284.
  • 6Liu M, Shi X, Jiang GL, et al. Long-term outcome of irradiation with or without chemotherapy for esophageal squamous cell car cinoma:a final report on a prospective trial [J]. Radiat Oncol, 2012,7:142.
  • 7Huang SH,Bayley A,Ringash J. et al. Effect of concurrent high- dose cisplatin chemotherapy and conformal radiotherapy on cervi- cal esophageal cancer survival[J]. Int J Radiat Oncol Phys,2008, 71(3) :735 740.
  • 8Kato H,Sato A,Fukuda H,et al. A phase ]J trial of chemoradio therapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study(JCOG9708)[J]. Jpn J Clin On- eol,2009,39(10) :638-643.
  • 9Shim H J, Kim DE, Cho SH,et al. A phase H study of concurrent ehemoradiotherapy with weekly docetaxel and cisplatin in ad- vanced oesophageal cancer [J]. Cancer Chemother Pharmacol, 2012,70(5) :683-690.
  • 10Kato K, Muro K, Fukuda H, et al. Phase lI study of chemoradio- therapy with 5 fluorouracil and eisplatin for Stage lI-[lI esopha geal squamous cell carcinoma:JCOG trial (JCOG 9906)[J]. Int J Radiat Oncol Biol Phys, 2011,81 (1) : 684-690.

引证文献4

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部